Drawing for INAGENE

USPTO serial 88255719

INAGENE

Reviewed by CopyMark Law Group

Reg. 7265522Status 700Registered
Filing date
Status date
Registration date
Jan 9, 2024
Examiner
SABAGH, LAILA TAREK
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with INAGENE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
035Advertising the goods and services of others focused on the application of personal genetic information for pain management, mental health and other comorbid conditions; developing promotional campaigns focused on the application of personal genetic information for pain management, mental health and other comorbid conditions, and marketing services, namely, marketing consultancy for businesses in the field of personal genetic information for pain management, mental health and other comorbid conditions, all the foregoing not including veterinary or plant applicationsACTIVE
041Providing online non-downloadable audio and video recordings containing information in the field of medical testing services, namely, genetic testing and genetic screening over a global computer networkACTIVE
042Genetic testing and genetic screening services for scientific research purposes; scientific research in the fields of genomics and genetics; scientific research in the application of personal genetic information with respect to medical or nutritional treatments, pharmaceuticals and clinical trials; providing genetic-based nutritional and pharmaceutical research information via the internet and via printed publications; providing clinical laboratory testing services, namely, pharmacogenetic tests, gene sequencing-based tests and genotyping based on the assessment, development and application of human genomic discoveries in the pharmaceutical, informatics and human clinical diagnostic industries, all the foregoing not including veterinary or plant applications; medical research in the fields of genomics and genetics; providing genetic-based medical research information via the internet and via printed publications; medical research in the fields of pharmacogenomics and pharmacogenetics; providing temporary use of on-line non-downloadable software applications related to medical conditions addressed by medical testing services, namely, platform as a service (PAAS) featuring computer software and mobile device applications for accessing information in the field of pain management, mental health and other comorbid conditions; providing genetic testing information for patients and healthcare professionals via an internet website portal; online services relating to medical testing services, namely, providing genetic testing and genetic screening information for patients and healthcare professionals via an internet website portalACTIVE
044Medical diagnostic testing services and providing medical information in the form of personalized reports online in the field of genetic testing for medical purposes; providing clinical laboratory testing services, namely, personalized medical tests based on the assessment, development and application of human genomic discoveries in the medical industry; online medical testing services, namely, genetic testing and genetic screening; Medical information services, namely, providing personalized information online in the field of genetic testing for medical purposes; medical information services, namely, reporting and providing feedback to patients and healthcare professionals on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, personal genetic information for pain management, mental health and other comorbid conditions and for understanding individual responses to medication, all the foregoing not including veterinary or plant applications; medical information services, namely, analyzing pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applications; medical information services, namely, preparation of reports on pharmacogenetic testing service results and relevance to medical and nutritional treatments, namely, analyzing individual pharmacogenetics and the interaction between personal genetic information and pharmaceuticals, all the foregoing not including veterinary or plant applicationsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 9, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 9, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 24, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 24, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 4, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2023FIXDELECTRONIC RECORD REVIEW COMPLETE
Sep 15, 2023ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Sep 8, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Sep 7, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 6, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 6, 2023GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jun 6, 2023GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jun 6, 2023CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Feb 15, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2023ALIEASSIGNED TO LIE
Feb 6, 2023ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Aug 6, 2022GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 6, 2022GNSIINQUIRY TO SUSPENSION E-MAILED
Aug 6, 2022CNSISUSPENSION INQUIRY WRITTEN
Jun 24, 2022RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 7, 2022DOCKASSIGNED TO EXAMINER
Dec 6, 2021RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 6, 2021GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 6, 2021GNSLLETTER OF SUSPENSION E-MAILED
Dec 6, 2021CNSLSUSPENSION LETTER WRITTEN
Jun 3, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Dec 3, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 3, 2020GNSLLETTER OF SUSPENSION E-MAILED
Dec 3, 2020CNSLSUSPENSION LETTER WRITTEN
Dec 3, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Dec 3, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 29, 2020ALIEASSIGNED TO LIE
Nov 2, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 1, 2020GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
May 1, 2020GNSIINQUIRY TO SUSPENSION E-MAILED
May 1, 2020CNSISUSPENSION INQUIRY WRITTEN
Nov 1, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 1, 2019GNSLLETTER OF SUSPENSION E-MAILED
Nov 1, 2019CNSLSUSPENSION LETTER WRITTEN
Oct 30, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Oct 30, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2019ALIEASSIGNED TO LIE
Oct 17, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 24, 2019GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Sep 24, 2019GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Sep 24, 2019EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Sep 24, 2019CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Aug 3, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Aug 2, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 2, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 25, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2019DOCKASSIGNED TO EXAMINER
Jan 30, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2019NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance